Business Context and Reporting Period
Lisata Therapeutics, Inc. (LSTA) filed a Form 8-K on October 8, 2025, reporting the entry into a Material Definitive Agreement. The Company is a Delaware corporation with its principal executive offices in Basking Ridge, NJ, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics and Agreement Terms
This filing details a Non-Exclusive License Agreement with Catalent, Inc. regarding the Company's iRGD cyclic peptide, certepetide, for use in Catalent's SMARTag ADC platform. Key financial terms include:
- Development Milestones: Eligible to receive up to $10.5 million in aggregate pre-determined payments.
- Revenue Sharing: Eligible for tiered revenue sharing on future sales and/or partnerships, subject to specified royalty reductions.
- Sublicensing: Eligible to receive a portion of any sublicense consideration.
- Cost Allocation: Catalent assumes full responsibility for research, development, and commercialization costs.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Operational Impact
The primary material change is the strategic partnership with Catalent, Inc. This agreement grants Catalent non-exclusive rights to exploit the Company's intellectual property. A significant operational shift is the transfer of financial risk for development and commercialization to Catalent. The agreement includes a Right of First Negotiation (ROFN) for Lisata should Catalent initiate an out-licensing process for assets resulting from the Agreement.
Guidance, Risks, and Contingencies
Termination Provisions: The agreement may be terminated by either party for material breach or insolvency. Catalent retains the right to terminate the entire agreement at any time with 30 days' prior written notice.
Duration: The agreement remains in effect until it expires on a product-by-product and country-by-country basis at the end of the royalty term.
Management Commentary: The filing does not contain specific forward-looking guidance or management commentary beyond the description of the agreement terms.
Investor Verification Checklist
- Verify the specific triggers and timelines for the $10.5 million in development milestone payments.
- Review the full text of the Non-Exclusive License Agreement (to be filed as an exhibit to the 2025 Form 10-K) for details on royalty reduction schedules and revenue sharing tiers.
- Assess the impact of Catalent's unilateral termination right on the Company's long-term revenue projections.
- Confirm the Company's current cash position and runway, as this filing does not disclose liquidity metrics.